Press Releases All News 2020 2019 2018 2017 2016 2015 2014 Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development March 24, 2020 Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development March 9, 2020 Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference February 25, 2020 Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer January 10, 2020 Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool December 20, 2019 Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares December 9, 2019 Relmada Therapeutics Announces Pricing of Public Offering of Common Stock December 3, 2019 Relmada Therapeutics Announces Proposed Public Offering of Common Stock December 3, 2019 Relmada to Ring NASDAQ Stock Market Opening Bell on Friday, October 18 October 17, 2019 Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression October 15, 2019 1 2 3 4 5 6 7 8 9 10 ...14 Next »
Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development March 24, 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development March 9, 2020
Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference February 25, 2020
Relmada Therapeutics Strengthens Financial Operations with Addition of Maged Shenouda as Chief Financial Officer January 10, 2020
Relmada Therapeutics Strengthens Board of Directors with Appointments of Life Sciences Industry Veterans, Eric Schmidt, Ph.D., and John Glasspool December 20, 2019
Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares December 9, 2019
Relmada Therapeutics Announces Top-Line Results from REL-1017 Phase 2 Study in Individuals with Treatment Resistant Depression October 15, 2019
